4//SEC Filing
FRATES JAMES M 4
Accession 0000950170-24-106910
CIK 0001658551other
Filed
Sep 15, 8:00 PM ET
Accepted
Sep 16, 5:30 PM ET
Size
7.1 KB
Accession
0000950170-24-106910
Insider Transaction Report
Form 4
FRATES JAMES M
Chief Financial Officer
Transactions
- Purchase
Common Stock
2024-09-12$2.53/sh+40,000$101,368→ 233,464 total
Holdings
- 15,459(indirect: By Trust)
Common Stock
- 11,072(indirect: By Trust)
Common Stock
Footnotes (3)
- [F1]The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $2.4849 to $2.63. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request.
- [F2]Shares held by the James M. Frates 2024 Grantor Retained Annuity Trust No. 1, for which the Reporting Person serves as trustee and is the sole annuitant. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.
- [F3]Shares held by the FRATES FAMILY 2013 IRREV TRUST, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.
Documents
Issuer
Amylyx Pharmaceuticals, Inc.
CIK 0001658551
Entity typeother
Related Parties
1- filerCIK 0001235598
Filing Metadata
- Form type
- 4
- Filed
- Sep 15, 8:00 PM ET
- Accepted
- Sep 16, 5:30 PM ET
- Size
- 7.1 KB